Table 3 Quality assessment of included studies
From: Factors influencing self-management in patients with epilepsy: a systematic review and meta-analysis
AHRQ | Thuy Le et al., [15] | Duran et al., [16] | Babaei et al., [20] | Smithson et al., [17] | Begley et al., [19] | McAuley et al., [18] | Jin et al., [22] | Shi et al., [21] | Bai et al., [24] | Xiao et al., [23] |
|---|---|---|---|---|---|---|---|---|---|---|
1) Define the source of information (survey, record review) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
2) List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
3) Indicate time period used for identifying patients | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
4) Indicate whether or not subjects were consecutive if not population-based | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
5) Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
6) Describe any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements) | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
7) Explain any patient exclusions from analysis | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
8) Describe how confounding was assessed and/or controlled. | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
9) If applicable, explain how missing data were handled in the analysis | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
10) Summarize patient response rates and completeness of data collection | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
11) Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 8 | 4 | 7 | 8 | 7 | 8 | 8 | 8 | 8 | 8 |
*Yes-1, No/Unclear-0 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |